Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired
immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is
complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes
that share the same metabolic pathway as antiretroviral drugs used for those living with
HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral
drug when co-administered with a common anti-tuberculosis regimen of drugs.